Comparison between CAR-T and TCR-T
As a matter of fact, tumor immunotherapy is divided into two categories. One is to show immune cells the tumor features, then direct them to locate and kill tumor cells. And anotherRead More…
All posts by biolabs
TCR, A New Star of Immune Cell Therapy
Immune cell therapy, the fourth major cancer treatment following surgery, radiotherapy, and chemotherapy, has been recognized as the most active and promising treatment in the comprehensive tumor treatment in the 21st century.Read More…
Signal, Migration and Survival of CAR T Cells
CAR-T, Chimeric AntigenReceptor T-Cell Immunotherapy, is the most effective treatment of malignant tumors. Similar to other immunotherapy, its basic principle is to remove cancer cells in the use of the patient’s ownRead More…
A New Immunotherapy Called CAR-T Will Beat Cancer Surprisingly
CAR-T (Chimeric Antigen Receptor T-Cell), as an immunocytotherapy regimen, has attracted a lot of attention from academics, doctors, patients, and investors worldwide. What does make it so attractive and popular? CAR-T modifiesRead More…
Membrane Protein Overview
Structural Classification of Membrane Proteins Membrane proteins represent about a third of the proteins in living organisms. Based on their structure, there are main three types of membrane proteins: the first oneRead More…
A Quick View of the Global R&D Situation of EGFR Drugs
1. There are 102 EGFR-targeted drugs that are approved globally and in clinical research in total. Up to now, there are 20 EGFR-targeted drugs approved by the global market (Europe, USA, Japan,Read More…
The First CAR-T Therapy Drug Is Approved and Recommended by FDA Experts Unanimously on a 10-0 Vote!
Novartis’ chimeric antigen receptor T cell therapy (CAR-T) was supported and approved unanimously (10-0) on July 12th by the U.S. FDA Advisory Committee experts. This vote marks the key milepost of thisRead More…
Will the First CAR-T Therapy Be Approved on July 12? —Novartis CTL019
On July 12, FDA experts will discuss whether CAR-T CTL019 can be on the market, which is an assessment of the CTL019 Biologics License Application (BLA) submitted by Novartis and will evaluateRead More…
Best Selling Anti-tumor Drugs in the Next 5 Years
According to the Journal of the American Medical Association, there were 15.4 million cancer patients worldwide in 2013. Among them, the cancer mortality rate in developing countries was higher than that ofRead More…
Antibody Diversity
Before we start to introduce the principle of antibody diversity, you’d better learn about structure of antibody. Antibody consists of two heavy chains and two light chains. Most antibody related research isRead More…